ClinicalTrials.gg
RecruitingNCT07457749Updated Mar 19, 2026

Clinical Performance of a Novel Self-cured Resin Composite Compared to a Light-cured Bioactive Resin Composite Restoration in Proximal Cavities of Posterior Teeth

An Early Phase 1 interventional study of Stela, SDI, Australia and Beautifil II, Shofu, Japan in Proximal Cavities of Posterior Teeth, sponsored by British University In Egypt. Recruiting at 1 site in Egypt. Open to participants aged 18 Years to 47 Years. Per ClinicalTrials.gov, last updated 2026-03-19.

Sponsored by British University In Egypt · Early Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Feb 2026; still recruiting 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Early Phase 1
Study type
Interventional
Enrollment
50
Allocation
Randomized
Ages
18 Years to 47 Years
Sex
All
01

Study summary

The development of dental caries is multi-factorial mainly due to the presence of 4 elements which are: dental biofilm, fermentable carbohydrates , dental hard tissue and time. Other additional social and environmental factors can have a substantial impact on the onset and course of the disease. Dietary habits, oral hygiene, salivary flow and fluoride exposure are key factors that influence the susceptibility to dental caries. If dental caries is properly managed, it is a preventable and reversible disease. The proximal teeth surfaces are the most susceptible sites for demineralization from the acidic byproducts. In modern restorative dentistry, clinicians always seek solutions that streamline procedures, improve outcomes and reduce chair time for patients. Traditional light-cured composite systems often involve a complex seven step process which includes etching, priming, bonding and curing which consumes from 90 to 120 seconds to be completed. With each additional step, the risk of technique errors increases, potentially compromising the longevity of the restoration. Self-cure composites, with their simplified application process, are emerging as a preferred choice over the traditional seven-step composite materials. Recently, a novel self-cured high-performance bulk-fill restorative material has been introduced into the market (Stela, SDI, Victoria, Australia). It's particularly known for its "unlimited" depth of cure and self-adhesive properties.

02

Conditions studied

  • Proximal Cavities of Posterior Teeth

Keywords

  • clinical performance
  • self-cured resin composite
  • bioactive
  • proximal cavities
03

In context

Lead sponsor

British University In Egypt is the lead sponsor of 70 studies on the registry; 22 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 47 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subjects between the ages of 18-47 years old
  2. Primary caries removal
  3. Good or moderate oral hygiene
  4. Free of periodontal diseases (probing depth and attachment levels within normal limits/ no furcation involvement/ no mobility)
  5. Cooperative patients who agree to keep the scheduled recall appointments for data collection and maintenance

Exclusion criteria

Exclusion Criteria:

  1. Composite or amalgam removal
  2. Caries extended to the cemento-enamel junction in Class II caries
  3. Grade II or III mobility
  4. Considerable periodontal disease without treatment
  5. Endodontically treated teeth with extensive loss of tooth tissues
  6. Severe wear facets and/or parafunctional activities as clenching or nocturnal bruxism.
  7. Subjects who are pregnant during the duration of the study
  8. Subjects with high caries activity
05

Study design

Phase
Early Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Outcomes assessor)
Enrollment
50 participants (estimated)

Study arms

  • Active comparator
    Beautifil II , Shofu (Light-cured Resin Composite)

    It is a light-cured bioactive nanohybrid resin composite restorative material

    Drug: Beautifil II, Shofu, Japan

  • Experimental
    Stela, SDI, Australia (Self-cured Resin Composite)

    It is a novel self-cured bulk-fill restorative material. It is offered in two application forms (Stela Automix \& Stela Capsule) that is used in combination with a proprietary adhesive primer (Stela Primer), which does not require light curing, but it undergoes polymerization upon contact with the restorative material in addition to its ability to generate minimal shrinkage stresses. The polymerization starting at the bottom of the cavity helps drastically reduce polymerization shrinkage stress, which is a common cause of post-operative sensitivity.

    Drug: Stela, SDI, Australia

Interventions

  • DrugStela, SDI, Australia

    Stela, (SDI ) is a novel self-cured bulkfill dental restorative material that is used in combination with an adhesive primer (Stela primer) which doesn't require light curing but it undergoes polymerization upon contact with the restorative material.

  • DrugBeautifil II, Shofu, Japan

    Beautifil II is a light-cured bioactive nanohybrid resin composite restorative material. It is a renowned Giomer (Glass-ionomer/composite hybrid) restorative material from Shofu. It is famous for its "S-PRG" (Surface Pre-Reacted Glass) technology, which allows it to release and recharge fluoride like a glass ionomer while maintaining the aesthetics and durability of a composite.

06

What researchers measure

Primary outcomes

  1. Proximal contact tightness of examined class II restorations

    This primary outcome will be measured using the FDI criteria for direct and indirect restorations

    Time frame: Baseline (after 1 week) and at 6, 12, 18, 24 months

Secondary outcomes

  1. Postoperative Hypersensitivity

    One-week post-operative hypersensitivity will be examined using a visual analogue scale following the FDI criteria (absence/presence of hypersensitivity).

    Time frame: Immediate post procedure and after 1 week

07

Study locations

1 of 1 sites recruiting
  • Faculty of Dentistry, The British University in Egypt
    Cairo, El Sherouk City 11837, Egypt
    Recruiting
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Feb 2026 (actual). Primary completion is estimated for Feb 2028, 24 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 4, 2026
First posted
Mar 9, 2026
StartActual
Feb 18, 2026
Primary completionEst.
Feb 18, 2028
CompletionEst.
Mar 18, 2028
Last update
Mar 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 19, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07457749
Lead sponsor
British University In Egypt
Responsible party
SARA SAWAF (Demonstrator at the Conservative Department, Faculty of Dentistry, The British University in Egypt, British University In Egypt) — Principal investigator
First posted
Mar 9, 2026
Start date
Feb 18, 2026
Primary completion
Feb 18, 2028 (estimated)
Completion
Mar 18, 2028 (estimated)
Last update
Mar 19, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion